Shelbi Atrash, MD
Hematology & Oncology · Charlotte, NCNPI 1417105941
Payments from drug & device makers
Across 326 payments — averaging $29,157 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4M
- Takeda Pharmaceuticals U.S.A., Inc.$1.3M
- GSK$1.1M
- Bristol Myers Squibb$1.1M
- Pfizer$890K
- Janssen Research & Development, LLC$683K
- plus $383K from 17 others
Across 10 payments — averaging $571.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4K
- GSK$2K
- AbbVie$113
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $4,045,087 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $1,311,227 |
| GSK | 22 | $1,114,930 |
| Bristol Myers Squibb | 18 | $1,078,025 |
| Pfizer | 41 | $889,763 |
| Janssen Research & Development, LLC | 60 | $683,093 |
| Karyopharm Therapeutics Inc. | 10 | $256,111 |
| Johnson & Johnson | 58 | $48,970 |
| Beone Medicines USA, Inc. | 7 | $48,717 |
| Sanofi | 28 | $18,052 |
| Janssen Scientific Affairs, LLC | 6 | $4,630 |
| E.r. Squibb & Sons, L.L.C. | 5 | $4,058 |
| Janssen Global Services, LLC | 1 | $1,430 |
| Menarini Silicon Biosystems, Inc. | 1 | $214 |
| AstraZeneca | 2 | $195 |
| Seagen Inc. | 1 | $114 |
| Regeneron Healthcare Solutions, Inc. | 1 | $114 |
| AbbVie | 1 | $107 |
| Merck | 1 | $106 |
| Astrazeneca UK Limited | 1 | $96 |
| F. Hoffmann-la Roche AG | 1 | $49 |
| Legend Biotech USA Inc. | 1 | $18 |
| Secura Bio, Inc. | 1 | $12 |
How this compares
$9,505,118 in reported general payments places this provider in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Charlotte
- Justin FavaroCharlotte$955K
- Kimberly GreenCharlotte$927K
- Joseph MerrimanCharlotte$663K
- Jennifer AtlasCharlotte$655K
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.